세계의 폐암 액체생검 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Lung Cancer Liquid Biopsy Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

US $ 4,995 ￦ 6,828,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 9,972,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 11,613,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

주요 조사 결과

• 폐암 액체생검 시장 규모 : 8억 2,470만 달러(2025년)
• 예상 시장 규모 : 19억 50만 달러(2032년)
• 세계 시장 성장률: 12.7%(2025-2032년 CAGR)

폐암 액체생검 시장 - 보고서 범위

폐암 액체생검 시장은 폐암 환자의 종양 바이오마커를 검출하기 위해 혈액 및 기타 체액을 사용하는 비침습적 진단 방법에 초점을 맞추었습니다. 이러한 생검은 빠른 시간, 환자의 불편감 감소, 종양 진행 및 치료 효과의 실시간 모니터링으로 암 진단 및 관리에 혁명을 일으키고 있습니다. 전 세계적으로 폐암 발병률이 증가하고 정밀의료의 도입이 증가함에 따라 액체생검은 종양 진단의 강력한 도구로 부상하고 있습니다. 이 시장에는 소세포폐암(SCLC)과 비소세포폐암(NSCLC)의 조기 발견, 유전자 프로파일링, 치료 방침 결정을 위해 설계된 기기, 시약, 바이오인포매틱스 솔루션 등 다양한 제품 및 서비스가 포함됩니다.

시장 성장 촉진요인

세계 폐암 액체생검 시장의 성장은 전 세계 폐암 유병률 증가와 최소침습적 진단법에 대한 수요 증가로 인해 크게 촉진되고 있습니다. 분자진단, 특히 차세대 염기서열 분석(NGS) 및 PCR 기반 기술의 발전은 액체생검 검사를 보다 정확하고 쉽게 이용할 수 있도록 돕고 있습니다. 또한, 개인 맞춤형 의료에 대한 관심이 높아지면서 의료 제공업체와 종양 전문의들이 실시간 종양 프로파일링 및 모니터링에 액체생검을 채택하고 있습니다. 규제 당국의 적극적인 승인과 특히 선진국에서 두드러진 의료비 증가는 시장 확대에 더욱 기여하고 있습니다. 또한, 조기 암 진단에 대한 선호도 증가와 기존 조직 생검의 한계를 극복할 수 있는 액체생검의 잠재력도 시장 수요를 촉진하고 있습니다.

시장 성장 억제요인

유망한 성장 궤도에도 불구하고 폐암 액체생검 시장은 여러 가지 주요 과제에 직면해 있습니다. 첨단 액체생검 기술의 높은 비용으로 인해 특히 중저소득 국가에서 채택이 제한될 수 있습니다. 일부 분석법의 민감도와 특이도는 특히 조기 암 발견에서 위양성 또는 위음성을 유발할 수 있어 여전히 우려되는 문제입니다. 일부 지역에서는 환자와 의료진의 낮은 인지도가 시장 침투에 걸림돌이 되기도 합니다. 또한, 엄격한 규제 프레임워크와 상환 장애물은 제품 출시를 지연시키거나 접근성을 제한하여 전체 시장 성장에 영향을 미칠 수 있습니다.

시장 기회

폐암 액체생검 시장은 진단 정확도를 높일 수 있는 세포외소포 및 순환 종양세포와 같은 새로운 바이오마커 연구의 확대로 인해 큰 기회를 제공합니다. 현재 진행 중인 다분석 액체생검 패널의 개발과 바이오인포매틱스에 AI와 머신러닝의 통합은 진단의 정확성과 효율성을 향상시킬 수 있는 길을 제공합니다. 특히 아시아태평양 및 라틴아메리카 등 신흥 경제국은 암 발병률 증가와 의료 인프라의 확장으로 인해 아직 개발되지 않은 잠재력을 가지고 있습니다. 또한, 표적치료의 동반진단을 위한 진단기업과 제약기업과의 제휴는 새로운 성장의 길을 열어주고 있습니다. 새로운 바이오마커 조합의 검증을 위한 연구개발과 임상시험에 대한 지속적인 투자는 기술 혁신과 시장에서의 경쟁력을 촉진할 것으로 보입니다.

이 보고서는 세계 폐암 액체생검 시장에 대해 조사했으며, 성장 촉진요인, 동향, 기회, 과제 등 시장 역학에 대한 상세한 분석을 제공합니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 범위와 정의
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 주요 동향
• 거시경제 요인
  • 세계의 부문 전망
  • 세계의 GDP 성장 전망
• COVID-19의 영향 분석
• 예측 요인 - 관련성과 영향

제3장 부가가치 인사이트

• 제품 채택 분석
• 질병 역학
• 규제 상황
• 공급업체 리스트
• Porter의 Five Forces 분석
• PESTLE 분석
• 프로모션 전략 : 주요 기업별

제4장 세계의의 폐암 액체생검 전망

• 주요 하이라이트
  • 시장 규모와 전년대비 성장
  • 절대적 매출 기회
• 시장 규모 분석과 예측
  • 시장 규모 분석(2019년-2024년)
  • 현재 시장 규모 분석과 예측(2025년-2032년)
• 세계의 폐암 액체생검 전망 : 제품
  • 서론/주요 조사 결과
  • 시장 규모 분석 : 제품별(2019년-2024년)
  • 현재 시장 규모 분석과 예측 : 제품별(2025년-2032년)
    • 기구
    • 키트 및 시약
    • 소프트웨어 및 서비스
  • 시장의 매력 분석 : 제품
• 세계의 폐암 액체생검 전망 : 기술
  • 서론/주요 조사 결과
  • 시장 규모 : 기술별(2019년-2024년)
  • 현재 시장 규모 분석과 예측 : 기술별(2025년-2032년)
    • 멀티 유전자 병렬 해석(NGS)
    • 단일 유전자 분석(PCR 마이크로어레이)
  • 시장의 매력 분석 : 기술
• 세계의 폐암 액체생검 전망 : 바이오마커
  • 서론/주요 조사 결과
  • 시장 규모 : 바이오마커별(2019년-2024년)
  • 현재 시장 규모 분석과 예측 : 바이오마커별(2025년-2032년)
    • cfDNA
    • ctDNA
    • 세포외소포(EV)
    • 순환종양세포(CTC)
    • 기타
  • 시장의 매력 분석 : 바이오마커
• 세계의 폐암 액체생검 전망 : 적응증
  • 서론/주요 조사 결과
  • 시장 규모 : 적응증별(2019년-2024년)
  • 현재 시장 규모 분석과 예측 : 적응증별(2025년-2032년)
    • 소세포 폐암(SCLC)
    • 비소세포 폐암(NSCLC)
  • 시장의 매력 분석 : 적응증
• 세계의 폐암 액체생검 전망 : 샘플
  • 서론/주요 조사 결과
  • 시장 규모, 샘플별(2019년-2024년)
  • 현재 시장 규모 분석과 예측 : 샘플별(2025년-2032년)
    • 혈액
    • 뇌척수액(CSF)
    • 혈장
    • 혈청
    • 기타
  • 시장의 매력 분석 : 샘플
• 세계의 폐암 액체생검 전망 : 최종사용자
  • 서론/주요 조사 결과
  • 시장 규모 : 최종사용자별(2019년-2024년)
  • 현재 시장 규모 분석과 예측 : 최종사용자별(2025년-2032년)
    • 병원
    • 참조 실험실
    • 학술연구기관
    • 기타
  • 시장의 매력 분석 : 최종사용자

제5장 세계의 폐암 액체생검 전망 : 지역

• 주요 하이라이트
• 시장 규모 분석 : 지역별(2019년-2024년)
• 현재 시장 규모 분석과 예측 : 지역별(2025년-2032년)
  • 북미
  • 유럽
  • 동아시아
  • 남아시아 및 오세아니아
  • 라틴아메리카
  • 중동 및 아프리카
• 시장의 매력 분석 : 지역

제6장 북미의 폐암 액체생검 전망

제7장 유럽의 폐암 액체생검 전망

제8장 동아시아의 폐암 액체생검 전망

제9장 남아시아 및 오세아니아의 폐암 액체생검 전망

제10장 라틴아메리카의 폐암 액체생검 전망

제11장 중동 및 아프리카의 폐암 액체생검 전망

제12장 경쟁 구도

• 시장 점유율 분석(2025년)
• 시장 구조
  • 경쟁 강도 맵 : 시장별
  • 경쟁 대시보드
• 기업 개요(상세 - 개요, 재무, 전략, 최근 발전)
  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Oncocyte Corporation
  • NeoGenomics Laboratories
  • Lepu Medical Technology(Beijing) Co., Ltd
  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd
  • Sysmex Corporation
  • BioView
  • Guardant Health, Inc
  • SOPHiA GENETICS
  • BioMark Diagnostics
  • DELFI Diagnostics, Inc.
  • Freenome Holdings, Inc.
  • Foresight Diagnostics, Inc.
  • Foundation Medicine, Inc.
  • Pillar Biosciences, Inc.
  • Caris Life Sciences

제13장 부록

LSH

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the global Lung Cancer Liquid Biopsy Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

• Lung Cancer Liquid Biopsy Market Size (2025E): US$ 824.7 Mn
• Projected Market Value (2032F): US$ 1,900.5 Mn
• Global Market Growth Rate (CAGR 2025 to 2032): 12.7%

Lung Cancer Liquid Biopsy Market - Report Scope:

The lung cancer liquid biopsy market focuses on non-invasive diagnostic methods that utilize blood and other body fluids to detect tumor biomarkers in lung cancer patients. These biopsies are revolutionizing cancer diagnostics and management by offering quicker turnaround times, reduced patient discomfort, and real-time monitoring of tumor progression or therapy response. With rising lung cancer incidence globally and increasing adoption of precision medicine, liquid biopsy is emerging as a powerful tool in oncology diagnostics. This market includes a wide range of products and services, including instruments, reagents, and bioinformatics solutions designed for early detection, genetic profiling, and therapeutic decision-making in both Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC).

Market Growth Drivers:

The growth of the global lung cancer liquid biopsy market is being significantly driven by the rising global prevalence of lung cancer, coupled with a growing demand for minimally invasive diagnostic procedures. Technological advancements in molecular diagnostics, particularly in next-generation sequencing (NGS) and PCR-based techniques, are making liquid biopsy tests more accurate and accessible. Additionally, increasing focus on personalized medicine is pushing healthcare providers and oncologists to adopt liquid biopsies for real-time tumor profiling and monitoring. Supportive regulatory approvals and increasing healthcare spending, especially in developed nations, are further contributing to market expansion. The growing preference for early and precise cancer detection methods and the potential of liquid biopsies to overcome limitations of traditional tissue biopsies are also propelling market demand.

Market Restraints:

Despite the promising growth trajectory, the lung cancer liquid biopsy market faces several key challenges. High costs associated with advanced liquid biopsy technologies can restrict adoption, particularly in low- and middle-income countries. The sensitivity and specificity of some assays, especially in early-stage cancer detection, remain areas of concern, potentially leading to false positives or negatives. Limited awareness among patients and healthcare providers in certain regions further impedes market penetration. Additionally, stringent regulatory frameworks and reimbursement hurdles can delay product launches and limit accessibility, affecting overall market growth.

Market Opportunities:

The lung cancer liquid biopsy market presents considerable opportunities fueled by the expansion of research into new biomarkers, including extracellular vesicles and circulating tumor cells, which can enhance diagnostic accuracy. The ongoing development of multi-analyte liquid biopsy panels and integration of AI and machine learning in bioinformatics offer pathways to improved diagnostic precision and efficiency. Emerging economies, especially across Asia-Pacific and Latin America, represent untapped potential with growing cancer burden and expanding healthcare infrastructure. Furthermore, collaborations between diagnostic companies and pharmaceutical firms for companion diagnostics in targeted therapies are opening new growth avenues. Continued investment in R&D and clinical trials aimed at validating new biomarker combinations will likely drive innovation and market competitiveness.

Key Questions Answered in the Report:

• What are the primary factors driving the global lung cancer liquid biopsy market's growth?
• Which regions and market segments are experiencing the highest demand for lung cancer liquid biopsy diagnostics?
• How are advancements in genomics and personalized oncology influencing market dynamics?
• Who are the key players in the lung cancer liquid biopsy market, and what strategies are they adopting to stay competitive?
• What are the emerging trends and future projections for the global lung cancer liquid biopsy market?

Competitive Intelligence and Business Strategy:

Leading players in the global lung cancer liquid biopsy market, such as Bio-Rad Laboratories, Agilent Technologies, Thermo Fisher Scientific, Illumina, and F. Hoffmann-La Roche, are focusing on developing high-sensitivity diagnostic platforms and expanding their liquid biopsy portfolios. These companies are increasingly investing in strategic collaborations with research institutions and biotech firms to enhance their R&D capabilities. Mergers, acquisitions, and licensing agreements are common strategies aimed at boosting technological integration and expanding global reach. Key players are also emphasizing regulatory approvals and global certifications to gain market trust and improve reimbursement prospects. Efforts to combine multiple biomarkers into single-panel tests and the integration of cloud-based platforms for data interpretation are setting new standards in the field.

Companies Covered in This Report:

• Bio-Rad Laboratories, Inc.
• Agilent Technologies, Inc.
• Oncocyte Corporation
• NeoGenomics Laboratories
• Lepu Medical Technology (Beijing) Co., Ltd
• QIAGEN
• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• F. Hoffmann-La Roche Ltd
• Sysmex Corporation
• BioView

Market Segmentation

By Product:

• Instruments
• Kits and Reagents
• Software and Services

By Technology:

• Multi-gene-parallel Analysis (NGS)
• Single Gene Analysis (PCR, Microarrays)

By Biomarker:

• Cell-free DNA (cfDNA)
• Circulating Tumor DNA (ctDNA)
• Extracellular Vesicles (EVs)
• Circulating Tumor Cells (CTC)
• Others

By Indication:

• Small Cell Lung Cancer (SCLC)
• Non-Small Cell Lung Cancer (NSCLC)

By Sample:

• Blood
• Cerebrospinal Fluid (CSF)
• Plasma
• Serum
• Others

By End-user:

• Hospitals
• Reference Laboratories
• Academic & Research Centers
• Others

By Region:

• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Lung Cancer Liquid Biopsy Snapshot, 2025-2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Product Adoption Analysis
• 3.2. Disease Epidemiology
• 3.3. Regulatory Landscape
• 3.4. List of Suppliers
• 3.5. Porter's Five Forces Analysis
• 3.6. PESTLE Analysis
• 3.7. Promotional Strategies, By Key Players

4. Global Lung Cancer Liquid Biopsy Outlook

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Mn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
  • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
• 4.3. Global Lung Cancer Liquid Biopsy Outlook: Product
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Product, 2019-2024
  • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 4.3.3.1. Instruments
    • 4.3.3.2. Kits and Reagents
    • 4.3.3.3. Software and Services
  • 4.3.4. Market Attractiveness Analysis: Product
• 4.4. Global Lung Cancer Liquid Biopsy Outlook: Technology
  • 4.4.1. Introduction / Key Findings
  • 4.4.2. Historical Market Size (US$ Mn), By Technology, 2019-2024
  • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
    • 4.4.3.1. Multi-gene-parallel Analysis (NGS)
    • 4.4.3.2. Single Gene Analysis (PCR Microarrays)
  • 4.4.4. Market Attractiveness Analysis: Technology
• 4.5. Global Lung Cancer Liquid Biopsy Outlook: Biomarker
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Mn), By Biomarker, 2019-2024
  • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
    • 4.5.3.1. Cell-free DNA (cfDNA)
    • 4.5.3.2. Circulating tumor DNA (ctDNA)
    • 4.5.3.3. Extracellular Vesicles (EVs)
    • 4.5.3.4. Circulating Tumor Cells (CTC)
    • 4.5.3.5. Others
  • 4.5.4. Market Attractiveness Analysis: Biomarker
• 4.6. Global Lung Cancer Liquid Biopsy Outlook: Indication
  • 4.6.1. Introduction / Key Findings
  • 4.6.2. Historical Market Size (US$ Mn), By Indication, 2019-2024
  • 4.6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 4.6.3.1. Small Cell Lung Cancer (SCLC)
    • 4.6.3.2. Non-Small Cell Lung Cancer (NSCLC)
  • 4.6.4. Market Attractiveness Analysis: Indication
• 4.7. Global Lung Cancer Liquid Biopsy Outlook: Sample
  • 4.7.1. Introduction / Key Findings
  • 4.7.2. Historical Market Size (US$ Mn), By Sample, 2019-2024
  • 4.7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
    • 4.7.3.1. Blood
    • 4.7.3.2. Cerebrospinal Fluid (CSF)
    • 4.7.3.3. Plasma
    • 4.7.3.4. Serum
    • 4.7.3.5. Others
  • 4.7.4. Market Attractiveness Analysis: Sample
• 4.8. Global Lung Cancer Liquid Biopsy Outlook: End User
  • 4.8.1. Introduction / Key Findings
  • 4.8.2. Historical Market Size (US$ Mn), By End User, 2019-2024
  • 4.8.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 4.8.3.1. Hospitals
    • 4.8.3.2. Reference Laboratories
    • 4.8.3.3. Academic & Research Institutes
    • 4.8.3.4. Others
  • 4.8.4. Market Attractiveness Analysis: End User

5. Global Lung Cancer Liquid Biopsy Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
• 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Lung Cancer Liquid Biopsy Outlook

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 6.2.1. By Country
  • 6.2.2. By Product
  • 6.2.3. By Technology
  • 6.2.4. By Biomarker
  • 6.2.5. By Indication
  • 6.2.6. By Sample
  • 6.2.7. By End User
• 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 6.4.1. Instruments
  • 6.4.2. Kits and Reagents
  • 6.4.3. Software and Services
• 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
  • 6.5.1. Multi-gene-parallel Analysis (NGS)
  • 6.5.2. Single Gene Analysis (PCR Microarrays)
• 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
  • 6.6.1. Cell-free DNA (cfDNA)
  • 6.6.2. Circulating tumor DNA (ctDNA)
  • 6.6.3. Extracellular Vesicles (EVs)
  • 6.6.4. Circulating Tumor Cells (CTC)
  • 6.6.5. Others
• 6.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 6.7.1. Small Cell Lung Cancer (SCLC)
  • 6.7.2. Non-Small Cell Lung Cancer (NSCLC)
• 6.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
  • 6.8.1. Blood
  • 6.8.2. Cerebrospinal Fluid (CSF)
  • 6.8.3. Plasma
  • 6.8.4. Serum
  • 6.8.5. Others
• 6.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 6.9.1. Hospitals
  • 6.9.2. Reference Laboratories
  • 6.9.3. Academic & Research Institutes
  • 6.9.4. Others
• 6.10. Market Attractiveness Analysis

7. Europe Lung Cancer Liquid Biopsy Outlook

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 7.2.1. By Country
  • 7.2.2. By Product
  • 7.2.3. By Technology
  • 7.2.4. By Biomarker
  • 7.2.5. By Indication
  • 7.2.6. By Sample
  • 7.2.7. By End User
• 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkey
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 7.4.1. Instruments
  • 7.4.2. Kits and Reagents
  • 7.4.3. Software and Services
• 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
  • 7.5.1. Multi-gene-parallel Analysis (NGS)
  • 7.5.2. Single Gene Analysis (PCR Microarrays)
• 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
  • 7.6.1. Cell-free DNA (cfDNA)
  • 7.6.2. Circulating tumor DNA (ctDNA)
  • 7.6.3. Extracellular Vesicles (EVs)
  • 7.6.4. Circulating Tumor Cells (CTC)
  • 7.6.5. Others
• 7.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 7.7.1. Small Cell Lung Cancer (SCLC)
  • 7.7.2. Non-Small Cell Lung Cancer (NSCLC)
• 7.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
  • 7.8.1. Blood
  • 7.8.2. Cerebrospinal Fluid (CSF)
  • 7.8.3. Plasma
  • 7.8.4. Serum
  • 7.8.5. Others
• 7.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 7.9.1. Hospitals
  • 7.9.2. Reference Laboratories
  • 7.9.3. Academic & Research Institutes
  • 7.9.4. Others
• 7.10. Market Attractiveness Analysis

8. East Asia Lung Cancer Liquid Biopsy Outlook

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 8.2.1. By Country
  • 8.2.2. By Product
  • 8.2.3. By Technology
  • 8.2.4. By Biomarker
  • 8.2.5. By Indication
  • 8.2.6. By Sample
  • 8.2.7. By End User
• 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 8.4.1. Instruments
  • 8.4.2. Kits and Reagents
  • 8.4.3. Software and Services
• 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
  • 8.5.1. Multi-gene-parallel Analysis (NGS)
  • 8.5.2. Single Gene Analysis (PCR Microarrays)
• 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
  • 8.6.1. Cell-free DNA (cfDNA)
  • 8.6.2. Circulating tumor DNA (ctDNA)
  • 8.6.3. Extracellular Vesicles (EVs)
  • 8.6.4. Circulating Tumor Cells (CTC)
  • 8.6.5. Others
• 8.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 8.7.1. Small Cell Lung Cancer (SCLC)
  • 8.7.2. Non-Small Cell Lung Cancer (NSCLC)
• 8.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
  • 8.8.1. Blood
  • 8.8.2. Cerebrospinal Fluid (CSF)
  • 8.8.3. Plasma
  • 8.8.4. Serum
  • 8.8.5. Others
• 8.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 8.9.1. Hospitals
  • 8.9.2. Reference Laboratories
  • 8.9.3. Academic & Research Institutes
  • 8.9.4. Others
• 8.10. Market Attractiveness Analysis

9. South Asia & Oceania Lung Cancer Liquid Biopsy Outlook

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 9.2.1. By Country
  • 9.2.2. By Product
  • 9.2.3. By Technology
  • 9.2.4. By Biomarker
  • 9.2.5. By Indication
  • 9.2.6. By Sample
  • 9.2.7. By End User
• 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 9.4.1. Instruments
  • 9.4.2. Kits and Reagents
  • 9.4.3. Software and Services
• 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
  • 9.5.1. Multi-gene-parallel Analysis (NGS)
  • 9.5.2. Single Gene Analysis (PCR Microarrays)
• 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
  • 9.6.1. Cell-free DNA (cfDNA)
  • 9.6.2. Circulating tumor DNA (ctDNA)
  • 9.6.3. Extracellular Vesicles (EVs)
  • 9.6.4. Circulating Tumor Cells (CTC)
  • 9.6.5. Others
• 9.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 9.7.1. Small Cell Lung Cancer (SCLC)
  • 9.7.2. Non-Small Cell Lung Cancer (NSCLC)
• 9.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
  • 9.8.1. Blood
  • 9.8.2. Cerebrospinal Fluid (CSF)
  • 9.8.3. Plasma
  • 9.8.4. Serum
  • 9.8.5. Others
• 9.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 9.9.1. Hospitals
  • 9.9.2. Reference Laboratories
  • 9.9.3. Academic & Research Institutes
  • 9.9.4. Others
• 9.10. Market Attractiveness Analysis

10. Latin America Lung Cancer Liquid Biopsy Outlook

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 10.2.1. By Country
  • 10.2.2. By Product
  • 10.2.3. By Technology
  • 10.2.4. By Biomarker
  • 10.2.5. By Indication
  • 10.2.6. By Sample
  • 10.2.7. By End User
• 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 10.4.1. Instruments
  • 10.4.2. Kits and Reagents
  • 10.4.3. Software and Services
• 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
  • 10.5.1. Multi-gene-parallel Analysis (NGS)
  • 10.5.2. Single Gene Analysis (PCR Microarrays)
• 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
  • 10.6.1. Cell-free DNA (cfDNA)
  • 10.6.2. Circulating tumor DNA (ctDNA)
  • 10.6.3. Extracellular Vesicles (EVs)
  • 10.6.4. Circulating Tumor Cells (CTC)
  • 10.6.5. Others
• 10.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 10.7.1. Small Cell Lung Cancer (SCLC)
  • 10.7.2. Non-Small Cell Lung Cancer (NSCLC)
• 10.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
  • 10.8.1. Blood
  • 10.8.2. Cerebrospinal Fluid (CSF)
  • 10.8.3. Plasma
  • 10.8.4. Serum
  • 10.8.5. Others
• 10.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 10.9.1. Hospitals
  • 10.9.2. Reference Laboratories
  • 10.9.3. Academic & Research Institutes
  • 10.9.4. Others
• 10.10. Market Attractiveness Analysis

11. Middle East & Africa Lung Cancer Liquid Biopsy Outlook

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 11.2.1. By Country
  • 11.2.2. By Product
  • 11.2.3. By Technology
  • 11.2.4. By Biomarker
  • 11.2.5. By Indication
  • 11.2.6. By Sample
  • 11.2.7. By End User
• 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
  • 11.4.1. Instruments
  • 11.4.2. Kits and Reagents
  • 11.4.3. Software and Services
• 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
  • 11.5.1. Multi-gene-parallel Analysis (NGS)
  • 11.5.2. Single Gene Analysis (PCR Microarrays)
• 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
  • 11.6.1. Cell-free DNA (cfDNA)
  • 11.6.2. Circulating tumor DNA (ctDNA)
  • 11.6.3. Extracellular Vesicles (EVs)
  • 11.6.4. Circulating Tumor Cells (CTC)
  • 11.6.5. Others
• 11.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
  • 11.7.1. Small Cell Lung Cancer (SCLC)
  • 11.7.2. Non-Small Cell Lung Cancer (NSCLC)
• 11.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
  • 11.8.1. Blood
  • 11.8.2. Cerebrospinal Fluid (CSF)
  • 11.8.3. Plasma
  • 11.8.4. Serum
  • 11.8.5. Others
• 11.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 11.9.1. Hospitals
  • 11.9.2. Reference Laboratories
  • 11.9.3. Academic & Research Institutes
  • 11.9.4. Others
• 11.10. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2025
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Bio-Rad Laboratories, Inc.
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Agilent Technologies, Inc.
  • 12.3.3. Oncocyte Corporation
  • 12.3.4. NeoGenomics Laboratories
  • 12.3.5. Lepu Medical Technology(Beijing)Co.,Ltd
  • 12.3.6. QIAGEN
  • 12.3.7. Thermo Fisher Scientific Inc.
  • 12.3.8. Illumina, Inc.
  • 12.3.9. F. Hoffmann-La Roche Ltd
  • 12.3.10. Sysmex Corporation
  • 12.3.11. BioView
  • 12.3.12. Guardant Health, Inc
  • 12.3.13. SOPHiA GENETICS
  • 12.3.14. BioMark Diagnostics
  • 12.3.15. DELFI Diagnostics, Inc.
  • 12.3.16. Freenome Holdings, Inc.
  • 12.3.17. Foresight Diagnostics, Inc.
  • 12.3.18. Foundation Medicine, Inc.
  • 12.3.19. Pillar Biosciences, Inc.
  • 12.3.20. Caris Life Sciences

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations

관련자료